


Company Profile:

Quantum Genomics (Alternext-FR0011648971 – ALQGC) is a biopharmaceutical company whose mission is to develop new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure. Quantum Genomics' research programs are based on the Brain Aminopeptidase A Inhibition (BAPAI), a real triple action innovative therapeutic platform, licensed from the academic research laboratories of the Collège de France, INSERM and CNRS. Quantum Genomics is the only biopharmaceutical company developing new therapies acting through brain aminopeptidase A inhibition.

A Robust Pipeline of new Drug Candidates



3 Reasons to be a shareholder

- QGC001: Lead Asset with Blockbuster Potential**
 - Currently in phase II for hypertension
 - Leading drugs facing patent expiration
- Breakthrough Therapeutic Class in a Huge Market**
 - \$79Bn annual sales market
 - >50% of patients lack proper treatment
 - 23m people worldwide suffer from heart failure today
- Robust Pipeline of New Drugs**
 - 3 components in development for hypertension
 - 1 component for congestive heart failure
 - Strong intellectual property portfolio

Stock Information

Exchange / Ticker: Euronext / ALQGC

Address


Tour Montparnasse
33 avenue du Maine
75015, Paris
FRANCE

Contact Information

Marc Karako, CFO & Investor Relations
Phone: +33 (0)1 85 34 77 75
Email: marc.karako@quantum-genomics.com
www.quantum-genomics.com

A Breakthrough Innovation

Inhibition of Aminopeptidase A



- ✓ Increase of the diuresis (urinary elimination)
- ✓ Lowering vascular resistance
- ✓ Controlling heart rate

BAPAIs are innovative drugs that target a new central pharmacological pathway leading to both antihypertensive effects and cardioprotection

Milestones

2015

2016



QGC001

✓ Patients enrollment of 50% and tolerance results

- Patients enrollment: 100%
- Results clinical trials phase IIa by end of June
- Optimization of galenic and pharmaceutical form



QGC011

- Results of repeated doses in hypertensive rats
- Results of PK & Tox repeated doses in rats

- Results of PK & Tox repeated doses in dogs



QGC006

- Non GMP batch production

- Results of unique dose in hypertensive rats



QGC101

✓ - Results on post infarction heart failure (dogs 28 days) in June
- Potential partnership agreement in animal health by end of December

- Start of phase IIa in humans by mid-year
- Results on post infarction heart failure (rats – 3 months)

Experienced Management Team



Lionel Segard
President & CEO

- Former CEO Inserm-Transfert
- Founder and former president of Inserm Transfert Initiative
- Founder of the Strategic Council for Innovation



Marc Karako
CFO

- Previously Executive VP & CFO of Carlson Wagonlit Travel
- Former CFO of Vallourec
- Former VP Finance at Thomson Multimedia
- 10 years at IBM



Jean-Philippe Milon
COO

- Management position at Bayer Health Care
- Head of Cardiovascular Business at Sandoz
- 25 years in healthcare and pharmaceutical industry



Olivier Madonna
CMO

- In-depth experience in R&D processes within biotech industries and development
- Former head of cardiovascular department with MSD and J&J
- MD, Cardiologist, Nephrologist



Fabrice Balavoine
VP R&D

- 15 years of in drug discovery and development
- Worked on development of several drugs that reached clinical stages in different therapeutic areas